异动解读 | 兆科眼科-B盘中大涨5.71%，三大重磅眼药临近上市

异动解读

Sep 01

兆科眼科-B（06622）今日盘中大涨5.71%，引发市场关注。消息面上，公司多个重磅眼科药物研发进展顺利，商业化进程加速，激发了投资者的信心。

据悉，兆科眼科目前有三大核心产品正在冲刺上市阶段。其中，用于儿童近视加深治疗的阿托品滴眼液（NVK002）双浓度规格已提交上市申请；治疗中重度干眼的环孢素眼用凝胶在国内已递交上市申请，美国III期临床试验也已获FDA批准；用于治疗湿性老年黄斑部病变的贝伐单抗注射液（TAB014）的BLA已获NMPA受理。这三款产品覆盖了近视防控、干眼症、黄斑病变等眼科高发领域，市场潜力巨大。

除了核心产品外，兆科眼科的研发管线也在稳步推进。公司的老花眼创新药物BRIMOCHOL™ PF正在进行II期临床试验，角膜修复药物ZKY001即将进入III期临床试验阶段。同时，公司还布局了前沿领域，如PAN-90806滴眼液和美法仑特殊剂型等。这些产品的研发进展为公司未来发展提供了强劲动力。此外，兆科眼科还在全球化布局、生产能力提升和销售网络构建方面取得了显著进展，为未来产品上市后的快速放量奠定了基础。市场普遍认为，随着公司核心产品陆续获批上市，兆科眼科有望迎来业绩快速增长期。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1162508469"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162508469\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162508469?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-09-01 10:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162508469","market":"nz","top_or_hot":-1,"title":"异动解读 | 兆科眼科-B盘中大涨5.71%，三大重磅眼药临近上市","media":"异动解读","content":"<p>兆科眼科-B（06622）今日盘中大涨5.71%，引发市场关注。消息面上，公司多个重磅眼科药物研发进展顺利，商业化进程加速，激发了投资者的信心。</p>\n\n<p>据悉，兆科眼科目前有三大核心产品正在冲刺上市阶段。其中，用于儿童近视加深治疗的阿托品滴眼液（NVK002）双浓度规格已提交上市申请；治疗中重度干眼的环孢素眼用凝胶在国内已递交上市申请，美国III期临床试验也已获FDA批准；用于治疗湿性老年黄斑部病变的贝伐单抗注射液（TAB014）的BLA已获NMPA受理。这三款产品覆盖了近视防控、干眼症、黄斑病变等眼科高发领域，市场潜力巨大。</p>\n\n<p>除了核心产品外，兆科眼科的研发管线也在稳步推进。公司的老花眼创新药物BRIMOCHOL™ PF正在进行II期临床试验，角膜修复药物ZKY001即将进入III期临床试验阶段。同时，公司还布局了前沿领域，如PAN-90806滴眼液和美法仑特殊剂型等。这些产品的研发进展为公司未来发展提供了强劲动力。此外，兆科眼科还在全球化布局、生产能力提升和销售网络构建方面取得了显著进展，为未来产品上市后的快速放量奠定了基础。市场普遍认为，随着公司核心产品陆续获批上市，兆科眼科有望迎来业绩快速增长期。</p>","source":"ai_movement_cn","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读 | 兆科眼科-B盘中大涨5.71%，三大重磅眼药临近上市</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读 | 兆科眼科-B盘中大涨5.71%，三大重磅眼药临近上市\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092702339\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">异动解读 </p>\n<p class=\"h-time\">2025-09-01 10:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>兆科眼科-B（06622）今日盘中大涨5.71%，引发市场关注。消息面上，公司多个重磅眼科药物研发进展顺利，商业化进程加速，激发了投资者的信心。</p>\n\n<p>据悉，兆科眼科目前有三大核心产品正在冲刺上市阶段。其中，用于儿童近视加深治疗的阿托品滴眼液（NVK002）双浓度规格已提交上市申请；治疗中重度干眼的环孢素眼用凝胶在国内已递交上市申请，美国III期临床试验也已获FDA批准；用于治疗湿性老年黄斑部病变的贝伐单抗注射液（TAB014）的BLA已获NMPA受理。这三款产品覆盖了近视防控、干眼症、黄斑病变等眼科高发领域，市场潜力巨大。</p>\n\n<p>除了核心产品外，兆科眼科的研发管线也在稳步推进。公司的老花眼创新药物BRIMOCHOL™ PF正在进行II期临床试验，角膜修复药物ZKY001即将进入III期临床试验阶段。同时，公司还布局了前沿领域，如PAN-90806滴眼液和美法仑特殊剂型等。这些产品的研发进展为公司未来发展提供了强劲动力。此外，兆科眼科还在全球化布局、生产能力提升和销售网络构建方面取得了显著进展，为未来产品上市后的快速放量奠定了基础。市场普遍认为，随着公司核心产品陆续获批上市，兆科眼科有望迎来业绩快速增长期。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06622","symbol_name":"兆科眼科-B","start_time":0,"source_url":"","article_id":"1162508469","we_media_id":"1092702339","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162508469","pubTimestamp":1756694912,"columns":[],"sourceInfo":{"source_id":"ai_movement_cn","name":"异动解读"},"weMediaInfo":{"media_name":"异动解读","introduction":"个股异动一手消息解读","home_visible":1,"id":"1092702339","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"兆科眼科-B今日盘中大涨5.71%，引发市场关注。据悉，兆科眼科目前有三大核心产品正在冲刺上市阶段。除了核心产品外，兆科眼科的研发管线也在稳步推进。此外，兆科眼科还在全球化布局、生产能力提升和销售网络构建方面取得了显著进展，为未来产品上市后的快速放量奠定了基础。市场普遍认为，随着公司核心产品陆续获批上市，兆科眼科有望迎来业绩快速增长期。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"06622":"兆科眼科-B"},"translate_title":"Interpretation of changes | Zhaoke Ophthalmology-B rose 5.71% in intraday trading, and three major blockbuster eye drops are about to be launched","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06622":1},"content_text":"兆科眼科-B（06622）今日盘中大涨5.71%，引发市场关注。消息面上，公司多个重磅眼科药物研发进展顺利，商业化进程加速，激发了投资者的信心。\n据悉，兆科眼科目前有三大核心产品正在冲刺上市阶段。其中，用于儿童近视加深治疗的阿托品滴眼液（NVK002）双浓度规格已提交上市申请；治疗中重度干眼的环孢素眼用凝胶在国内已递交上市申请，美国III期临床试验也已获FDA批准；用于治疗湿性老年黄斑部病变的贝伐单抗注射液（TAB014）的BLA已获NMPA受理。这三款产品覆盖了近视防控、干眼症、黄斑病变等眼科高发领域，市场潜力巨大。\n除了核心产品外，兆科眼科的研发管线也在稳步推进。公司的老花眼创新药物BRIMOCHOL™ PF正在进行II期临床试验，角膜修复药物ZKY001即将进入III期临床试验阶段。同时，公司还布局了前沿领域，如PAN-90806滴眼液和美法仑特殊剂型等。这些产品的研发进展为公司未来发展提供了强劲动力。此外，兆科眼科还在全球化布局、生产能力提升和销售网络构建方面取得了显著进展，为未来产品上市后的快速放量奠定了基础。市场普遍认为，随着公司核心产品陆续获批上市，兆科眼科有望迎来业绩快速增长期。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}